The European Medicines Agency (EMA) has accepted the submission by Eisai of an application to extend the use of adjunctive epilepsy treatment Zonegran® (zonisamide) in the treatment of partial seizures (with or without secondary generalisation) to include children aged six years and above. A decision on this new licence extension application is expected in September 2012...

Read the original article
Brought to you by Yahoo! News

Return to Epilepsy News